TAP Prevacid pediatric indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
TAP's proton pump inhibitor Prevacid (lansoprazole) clears FDA July 31 for the short-term treatment of symptomatic gastroesophageal reflux disease and erosive esophagitis in children one to 11 years old. The Abbott/Takeda joint venture is highlighting Prevacid as the only PPI available in an oral suspension formulation, a potential advantage for children who have difficulty swallowing capsule
You may also be interested in...
New China COVID Vaccine Arriving But COVAX Pledge May Need A Booster
China’s first domestically-developed recombinant protein vaccine for COVID-19 moves forward in late-stage trials in two countries.
QUOTED. 9 March 2021. Matthew Trerotola.
Splitting Colfax into separate fabrication technology and specialty medical technology businesses will help both sides of the business grow, CEO Matthew Trerotola said recently.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: